MXPA04001886A - Derivados de piperidina utiles como antagonistas de ccr5. - Google Patents

Derivados de piperidina utiles como antagonistas de ccr5.

Info

Publication number
MXPA04001886A
MXPA04001886A MXPA04001886A MXPA04001886A MXPA04001886A MX PA04001886 A MXPA04001886 A MX PA04001886A MX PA04001886 A MXPA04001886 A MX PA04001886A MX PA04001886 A MXPA04001886 A MX PA04001886A MX PA04001886 A MXPA04001886 A MX PA04001886A
Authority
MX
Mexico
Prior art keywords
compound
treatment
combination
derivatives useful
piperidine derivatives
Prior art date
Application number
MXPA04001886A
Other languages
English (en)
Inventor
W Miller Michael
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA04001886A publication Critical patent/MXPA04001886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion provee un compuesto de formula (I) (ver formula) o una de sus sales o solvatos aceptables farmaceuticamente, en la cual R1, R2, R3, R9, R10, A y B son como se definio en la especificacion; la presente invencion tambien provee composiciones farmaceuticas que contienen el compuesto de la invencion, y metodos de tratamiento que utilizan el compuesto de la invencion; la invencion tambien se refiere al uso de una combinacion de un compuesto de esta invencion y uno o mas agentes antivirales u otros agentes utiles en el tratamiento del virus de lnmunodeficiencia Humana (VIH); la invencion se refiere asimismo al uso de un compuesto de esta invencion, solo o en combinacion con otro agente, en el tratamiento del rechazo al trasplante de organos solidos, de la enfermedad injerto vs. huesped, de la artritis, de la artritis reumatoide, de la enfermedad inflamatoria del intestino, de la dermatitis atopica, de la soriasis, del asma, de las alergias o de la esclerosis multiple.
MXPA04001886A 2001-08-29 2002-08-28 Derivados de piperidina utiles como antagonistas de ccr5. MXPA04001886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31568301P 2001-08-29 2001-08-29
PCT/US2002/027389 WO2003020716A1 (en) 2001-08-29 2002-08-28 Piperidine derivatives useful as ccr5 antagonists

Publications (1)

Publication Number Publication Date
MXPA04001886A true MXPA04001886A (es) 2004-06-15

Family

ID=23225580

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001886A MXPA04001886A (es) 2001-08-29 2002-08-28 Derivados de piperidina utiles como antagonistas de ccr5.

Country Status (24)

Country Link
US (4) US20040010008A1 (es)
EP (1) EP1421075B1 (es)
JP (2) JP4223950B2 (es)
KR (1) KR20040029057A (es)
CN (1) CN1304389C (es)
AR (1) AR036366A1 (es)
AT (1) ATE328879T1 (es)
BR (1) BR0212108A (es)
CA (1) CA2457861A1 (es)
CY (1) CY1105198T1 (es)
DE (1) DE60212146T2 (es)
DK (1) DK1421075T3 (es)
EC (1) ECSP044993A (es)
ES (1) ES2264491T3 (es)
HK (1) HK1061563A1 (es)
HU (1) HUP0402019A3 (es)
IL (1) IL160060A0 (es)
MX (1) MXPA04001886A (es)
NO (1) NO20041266L (es)
PL (1) PL368827A1 (es)
PT (1) PT1421075E (es)
RU (1) RU2004109510A (es)
WO (1) WO2003020716A1 (es)
ZA (1) ZA200401594B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
WO2003004487A1 (en) 2001-07-02 2003-01-16 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
US20040082612A1 (en) * 2002-10-15 2004-04-29 Baxter Ellen W Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
JP4757802B2 (ja) * 2003-11-03 2011-08-24 シェーリング コーポレイション ケモカインレセプターの阻害剤として有用なビピペリジニル誘導体
WO2005047249A1 (en) * 2003-11-10 2005-05-26 Schering Aktiengesellschaft Benzylether amine compounds useful as ccr-5 antagonists
NZ550370A (en) 2004-04-13 2009-09-25 Incyte Corp Piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
JP2008528477A (ja) * 2005-01-20 2008-07-31 ファイザー・リミテッド 化合物
AR055313A1 (es) * 2005-02-23 2007-08-15 Schering Corp Derivados piperidinil piperidina utiles como inhibidores de receptores de quimioquinas. proceso de obtencion y composiciones farmaceuticas
US20070010565A1 (en) * 2005-04-25 2007-01-11 Olaf Prien New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
KR20080037655A (ko) 2005-07-21 2008-04-30 아스트라제네카 아베 신규 피페리딘 유도체
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
KR20100050570A (ko) * 2007-10-01 2010-05-13 에프. 호프만-라 로슈 아게 Ｃｃｒ 수용체 길항제로서의 ｎ-헤테로사이클릭 바이아릴 카복스아마이드
WO2009153182A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamide derivatives
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
KR20160098424A (ko) 2013-12-19 2016-08-18 바이엘 파마 악티엔게젤샤프트 치환된 피페리디닐-테트라히드로퀴놀린
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
EP3083610A1 (de) 2013-12-19 2016-10-26 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
CA2934132A1 (en) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
BR112017019437A2 (pt) 2015-04-02 2018-05-02 Proximagen Ltd terapias para câncer
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588722A (en) * 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
EP0912515B1 (en) * 1996-07-10 2002-11-13 Schering Corporation 1,4-di-substituted piperidines as muscarinic antagonists
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
WO2000066559A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
PL368827A1 (en) 2005-04-04
US7384948B2 (en) 2008-06-10
DK1421075T3 (da) 2006-09-18
RU2004109510A (ru) 2005-10-20
EP1421075B1 (en) 2006-06-07
US7442703B2 (en) 2008-10-28
US20040092745A1 (en) 2004-05-13
ECSP044993A (es) 2004-04-28
CN1304389C (zh) 2007-03-14
JP2005502682A (ja) 2005-01-27
BR0212108A (pt) 2004-08-24
US20040092551A1 (en) 2004-05-13
HK1061563A1 (en) 2004-09-24
IL160060A0 (en) 2004-06-20
CN1551877A (zh) 2004-12-01
NO20041266L (no) 2004-03-26
PT1421075E (pt) 2006-10-31
KR20040029057A (ko) 2004-04-03
DE60212146T2 (de) 2007-06-06
ATE328879T1 (de) 2006-06-15
ZA200401594B (en) 2004-11-24
ES2264491T3 (es) 2007-01-01
EP1421075A1 (en) 2004-05-26
AR036366A1 (es) 2004-09-01
JP4223950B2 (ja) 2009-02-12
HUP0402019A2 (hu) 2005-02-28
US8034933B2 (en) 2011-10-11
CA2457861A1 (en) 2003-03-13
DE60212146D1 (de) 2006-07-20
JP2008222722A (ja) 2008-09-25
CY1105198T1 (el) 2010-03-03
US20080214575A1 (en) 2008-09-04
HUP0402019A3 (en) 2009-07-28
US20040010008A1 (en) 2004-01-15
WO2003020716A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
MXPA04001886A (es) Derivados de piperidina utiles como antagonistas de ccr5.
TR200402496T2 (tr) CCR5 antagonistleri olarak yararlı piperidin türevleri.
CA2371583A1 (en) Piperazine derivatives useful as ccr5 antagonists
RS101304A (sr) Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi
MY132106A (en) New pyridazin-3(2h)-one derivatives
DE602004024375D1 (de) Carboxamidderivate
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
MY137535A (en) New pyrrolidinium derivatives
HRP20040317A2 (en) 1,8-naphthyridine derivatives as antidiabetics
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
WO2002083667A3 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
ATE386725T1 (de) Heterocyclylverbindungen
TW200616636A (en) Novel compounds
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
SE0302116D0 (sv) Novel compounds
MXPA04004263A (es) Hidrazono-malonitrilos.
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
YU73502A (sh) Farmaceutski aktivni derivati pirolidina
MA26418A1 (fr) Piperidones, procedes pour leur preparation et compositions pharmaceutiques les contenant
MY147899A (en) Piperidine derivatives useful as ccr5 antagonists
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
WO2005042517A3 (en) Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
TW200745087A (en) CCR5 antagonists useful for treating HIV
TW200640910A (en) Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
TW200640909A (en) Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors

Legal Events

Date Code Title Description
FG Grant or registration